august 24 2025 glp-1 GLP-1s: The world's first longevity drug? How Pharmacy Plans Are Managing

SHANGHAI, March 6 () - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions in coming years.The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk, Eli Lilly, and Innovent Biologics.

Unfortunately, being overweight is linked to a long list of health issues

Find upcoming conference details & earn CME/CE Credits.

Requires medical evaluation and approval by a licensed provider

And that trend has only been growing over the last four years

In conclusion, cannabis administration in this study modulated blood concentrations of some appetitive and metabolic hormones, chiefly insulin, in cannabis users